MIAMI--EPL Ventures here has entered into a $5 million option agreement to buy half of the outstanding shares of bioinformatics software company Savant Bio medical. Savant acquires and manages bioinformatics software, DNA sequencing database products and services, and cell and gene research technology and products.

The deal involves a private placement of 2.4 million units at a price of 25 cents each. A unit consists of one common share and a share purchase warrant entitling the holder to buy another share for $1 within one year of the date of acquisition of the units.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.